The Deal
Marvell (MRVL) announced this month a plan to buy Lumentum (LITE) for $115 billion in an all-stock deal. The offer works out to just over $1,100 per share. Marvell shareholders would own about two-thirds of the combined company. MRVL trades at $169 and change, well off its summer highs but recovering. Year to date it is up about 100%, running close to Lumentum, which is up 82% for 2026.
Why the Market Hated It
The market does not like the deal right now. In five or six trading sessions after the announcement, about $85 billion was wiped off Marvell's value - roughly 75 cents on the dollar of its share price, tied to this deal alone.
There is 18 months until close, with several hurdles to clear. Lumentum last traded at about 3.9 times versus the 4.5 times share deal. The risk premium, the gap, sits around 15-16% over that 18 months. A pure arbitrage play - short MRVL, long LITE - pays only about 15% over the 18-month window if the deal closes. That is a thin return for the risk.
The deeper problem is dilution and price. Arbitrage traders face immediate share dilution, with 50% of shares added. The valuation was rich: three weeks before the deal was signed, both stocks sat near all-time highs. The $115 billion tag puts the deal at 38 times adjusted earnings per share and 23 times the revenue pace. Those could be cycle-top numbers. The open question is whether the deal was made at the top.
There is history that rhymes, going back to the dot-com era. Lumentum is a spin-off of JDS Uniphase. When JDS Uniphase bid for an optics manufacturer, it paid about $41 billion. That turned out to be a terrible deal, written off in the largest write-off in company history. The market is skittish for that reason.
Both businesses are growing and have posted strong profits and gross margins. Stripping out the write-off on Lumentum's side, Lumentum was profitable this quarter. The business logic - owning Lumentum for vertical integration across its pipeline - makes sense. It comes down to the math, and with investors unsure what the return will look like, the deal is being discounted heavily as the wrong move for the current environment.
The Bull Case
On paper, guaranteed synergies are about $1 billion in cost savings, which is small against a $115 billion deal. The real bet is on compute demand. If demand stays strong and compounds into 2030, the market projection is around $100 billion, which would make this a great investment.
The core of the bull case: you are buying the bottleneck. Lumentum is one of maybe two or three suppliers that can produce at the needed scale and level and act as a good partner. Buying it means buying the constraint in AI and compute power, which gives a lead over rivals.
Demand looks real. Trade groups behind Microsoft (MSFT) and other tech companies are lobbying the government to let the Chinese off the hook, because there is not enough of this hardware to go around for the data center buildout.
The unknown is whether AI demand lasts. It sounds like the old claim that AI demand is insatiable - similar to when optics and fiber were being installed and internet traffic was said to double month over month. At some point that falls off. The strategy and vertical-integration logic are sound, but the numbers are big, and the deal math could fall through.
How to Trade It
The all-stock structure is what threw a wrench into the share price. MRVL is down over 40% from its all-time highs. Earnings land on December 1. Earnings have been great over the past couple of quarters, and the question is whether that continues and lifts the stock.
One approach is a two-part strategy: sell option premium, which is elevated now because volatility has expanded, while staying willing to buy the shares if the stock reverses and falls. Using the November 27th weekly options, which expire in 16 days, this avoids the earnings event and profits on consolidation, more upside, or even a pullback.
The trade: sell a cash-secured put, neutral to bullish, at the 148 strike, out of the money to the downside. You collect a credit of about $310 per put (possibly a little less, since the stock has kept rising). The break-even is about 144.90, roughly 14.5% below the current share price - a large cushion. The probability of the short 148 put finishing out of the money, letting you keep the credit, is about 77%. If the stock does fall below 148, you must buy the shares, but at about 144.90, a 14% discount to current levels.
MRVL is up 12% right now.
